Shots:
- The US FDA has granted BLA approval of Nypozi (TX01), biosimilar version of Amgen’s Neupogen
- Nypozi (TX01) is intended to reduce the incidence of infection among patients having non-myeloid malignancies undergoing chemotherapy that may reduce neutrophil count
- The company’s Nypozi was introduced across Canada in Jan 2024
Ref: Tanvex BioPharma | Image: Tanvex BioPharma | Press Release
Related News:- Alvotech and Advanz Pharma Team Up to Commercialize AVT06/AVT29 (Biosimilar, Eylea) in Europe
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
